Sign in

    Dylan Finley

    Senior Equity Analyst at B. Riley Securities

    Dylan Finley is a Senior Equity Analyst at B. Riley Securities, specializing in technology sector research and covering key companies such as Meta Platforms, Snap, and The Trade Desk. He is distinguished by his strong investment performance track record, including a success rate exceeding 60% and ranked among the top 15% of Wall Street analysts by TipRanks for returns generated in recent years. Finley began his career in equity research after earning a bachelor's degree in economics from the University of Chicago and later attained the Chartered Financial Analyst® designation. His professional credentials include the CFA charter and securities licenses, and he has earned recognition for insightful industry coverage and consistent investment performance.

    Dylan Finley's questions to DENTSPLY SIRONA (XRAY) leadership

    Dylan Finley's questions to DENTSPLY SIRONA (XRAY) leadership • Q2 2025

    Question

    Dylan Finley of UBS Group, on behalf of Kevin Caliendo, asked for an update on tariff cost assumptions and mitigation efforts. He also inquired about any financial adjustments related to BiTE and the performance of SureSmile in the U.S. market.

    Answer

    CFO Matt Garth clarified that the annualized tariff impact estimate has increased from $50 million to approximately $80 million, though the 2025 impact remains around $25 million. He noted a $4 million adjustment for BiTE in Q2 but anticipates no further changes. Regarding SureSmile, he reported 3.3% overall growth but acknowledged some softness in the U.S., which is being addressed through new education programs.

    Ask Fintool Equity Research AI

    Dylan Finley's questions to DENTSPLY SIRONA (XRAY) leadership • Q1 2025

    Question

    Dylan Finley, on for Kevin Caliendo, questioned the sustainability of the Orthodontic and Implant Solutions (OIS) segment's EBIT margin and asked for context on the second-quarter EPS guidance, which seems to imply a softer back half of the year.

    Answer

    CEO Simon Campion indicated that the Q1 adjusted EBITDA margin performance is a reasonable indicator for the rest of the year, driven by disciplined SG&A management. He attributed the Q2 EPS outlook to normal seasonality and noted that a larger portion of the tariff impact is expected in the second half of the year.

    Ask Fintool Equity Research AI

    Dylan Finley's questions to ZimVie (ZIMV) leadership

    Dylan Finley's questions to ZimVie (ZIMV) leadership • Q1 2025

    Question

    Dylan Finley of B. Riley Securities inquired about the drivers behind the April uptick in implant unit sales and the current pricing dynamics within the dental portfolio, including the capacity to offset tariff impacts with price increases.

    Answer

    Vafa Jamali, an executive, explained that the sales improvement was primarily driven by better same-store sales and strong initial performance from the new immediate molar implant system. Regarding pricing, Jamali noted that the premium implant market is less competitive on price. He stated that ZimVie would be highly selective about price increases to offset tariffs, using market segmentation to raise prices on certain products while avoiding competitive disadvantages on others.

    Ask Fintool Equity Research AI